BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings season will focus on commercial launches for the analyst’s small to mid cap biotech coverage, conversation around pharma tariffs, tax impact, and FDA turnover “should provide an additional overlay to sentiment,” the analyst tells investors in a preview for the group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Largest borrow rate increases among liquid names
- ‘Buy these Stocks that Innovate,’ Says Cathie Wood
- Crispr Therapeutics AG: Strong Market Position and Financial Stability Justify Buy Rating
- Crispr Therapeutics granted orphan status for follicular lymphoma treatment
- Crispr Therapeutics call volume above normal and directionally bullish